Literature DB >> 33169922

A prospective study monitoring carer distress during (chemo)radiotherapy for head and neck cancer via an electronic platform.

Laurelie R Wishart1,2, Bena Brown1,2,3, Rebecca L Nund1,2, Elena Fotinos1, Alana R Hutchison1, Elizabeth C Ward1,2, Sandro V Porceddu4,5.   

Abstract

INTRODUCTION: Research has shown that electronic platforms can assist data capture of patient-reported outcome measures (PROMs) to guide clinical care. In comparison, routine collection of carer-reported outcome measures (CROMs) to support the patient-carer dyad during cancer treatment has had limited attention. The current study utilised a novel electronic CROM (eCROM) system, ScreenIT Carer, to monitor the prevalence and nature of distress in carers of patients undergoing (chemo)radiotherapy ((C)RT) for head/neck cancer (HNC), and explore factors associated with carer distress.
METHODS: Carers completed ScreenIT Carer weekly when attending patients' (C)RT treatment sessions from planning to 2 weeks post-treatment. ScreenIT Carer included the Distress Thermometer (DT) and Problem List, and a purpose-built Mealtime-Specific DT and Problem list. Data were first examined descriptively, then associations between demographic/treatment-related factors and distress severity were analysed using mixed-effects general linear modelling.
RESULTS: 135 carers provided 434 ScreenIT Carer entries during the study period (mean entries = three/carer; yielding average adherence rate of 41% (range 11-100%)). A high prevalence of general (59%) and mealtime-specific distress (46%) was reported by carers. Nature of distress was multifactorial, with emotional problems and the patients' physical condition/symptoms common contributing factors. Based on multivariate analysis, tumour site, geographical location of residence and time during (C)RT when ScreenIT Carer was completed were significant predictors of carer distress severity.
CONCLUSIONS: Carer distress is prevalent and multifactorial during (C)RT. This study highlights the feasibility of utilising eCROM platforms such as ScreenIT Carer, to monitor carer wellbeing and guide supportive care services as part of a holistic care pathway.
© 2020 The Authors. Journal of Medical Radiation Sciences published by John Wiley & Sons Australia, Ltd on behalf of Australian Society of Medical Imaging and Radiation Therapy and New Zealand Institute of Medical Radiation Technology.

Entities:  

Keywords:  (Chemo)radiotherapy; distress; dysphagia; head and neck cancer; patient-reported outcomes; speech pathology

Year:  2020        PMID: 33169922     DOI: 10.1002/jmrs.448

Source DB:  PubMed          Journal:  J Med Radiat Sci        ISSN: 2051-3895


  4 in total

1.  A qualitative comparison of the nutrition care experiences of carers supporting patients with head and neck cancer throughout surgery and radiation treatment and survivorship.

Authors:  Joanne Hiatt; Adrienne Young; Teresa Brown; Merrilyn Banks; Bronwyn Segon; Judith Bauer
Journal:  Support Care Cancer       Date:  2022-09-16       Impact factor: 3.359

2.  "My life's not my own": A qualitative study into the expectations of head and neck cancer carers.

Authors:  Rhys Weaver; Moira O'Connor; Raelee M Golding; Chandrika Gibson; Rohen White; Melanie Jackson; Danette Langbecker; Anna Maria Bosco; Maureen Tan; Georgia K B Halkett
Journal:  Support Care Cancer       Date:  2022-01-23       Impact factor: 3.359

Review 3.  Telepractice and Dysphagia Management: The Era of COVID-19 and Beyond.

Authors:  Elizabeth C Ward; Madeline Raatz; Jeanne Marshall; Laurelie R Wishart; Clare L Burns
Journal:  Dysphagia       Date:  2022-04-15       Impact factor: 2.733

4.  ChromoEnhancer: An Artificial-Intelligence-Based Tool to Enhance Neoplastic Karyograms as an Aid for Effective Analysis.

Authors:  Yahya Bokhari; Areej Alhareeri; Abdulrhman Aljouie; Aziza Alkhaldi; Mamoon Rashid; Mohammed Alawad; Raghad Alhassnan; Saad Samargandy; Aliakbar Panahi; Wolfgang Heidrich; Tomasz Arodz
Journal:  Cells       Date:  2022-07-20       Impact factor: 7.666

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.